Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma

Figure 1 Proliferation of LM3 cells cocultured with monocytes. A: The proliferation of LM3 liver cancer cells cocultured with monocytes from patients in the transcatheter arterial chemoembolization combined with donafenib group (T + D) after three weeks of treatment were the lowest, followed by those from the transcatheter arterial chemoembolization combined with lenvatinib group (T + L); B and C: Using LM3 cells co cultured with monocytes for subcutaneous tumorigenesis in nude mice, the tumor weight was the lowest after coculture with monocytes from the T + D group, followed by those from the T + L group. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, ns: No significance. OD: Optical density; T + A: Transcatheter arterial chemoembolization combined with apatinib group; T + L: Transcatheter arterial chemoembolization combined with lenvatinib group; T + S: Transcatheter arterial chemoembolization combined with sorafenib group; T + D: Transcatheter arterial chemoembolization combined with donafenib group.